已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and efficacy of endovascular thrombectomy for primary and secondary MeVO

闭塞 穿孔 医学 冲程(发动机) 外科 内科学 机械工程 材料科学 冲孔 工程类 冶金
作者
Angelo Cascio Rizzo,Ghil Schwarz,Amedeo Cervo,Giuditta Giussani,Chiara Ceresa,Antonella Gatti,Fausto De Angeli,Cristina Motto,Angelo Guccione,Rachele Tortorella,Giuseppe Granata,Claudia Rollo,Antonio Macera,Mariangela Piano,Guglielmo Pero,Elio Clemente Agostoni
出处
期刊:Journal of stroke and cerebrovascular diseases [Elsevier BV]
卷期号:33 (1): 107492-107492 被引量:6
标识
DOI:10.1016/j.jstrokecerebrovasdis.2023.107492
摘要

Abstract

Background

Medium-vessel occlusions (MeVO) are emerging as a new target for endovascular treatment (EVT). Primary MeVO occur de novo, while secondary MeVO arise from large vessel occlusion (LVO) through clot migration or fragmentation - spontaneously, following intravenous thrombolysis or EVT. We aimed to evaluate efficacy and safety of EVT in primary and EVT-induced secondary MeVO.

Methods

Retrospective single-center study on consecutive EVT-treated acute ischemic stroke, from 2019-to-2021. We considered: (1) exclusive-LVO, patients with LVO and – in case of residual distal occlusion – no rescue endovascular procedure; (2) primary MeVO: initial A2, A3, M2 non-dominant, M3, P2, P3 occlusions; (3) EVT-induced secondary MeVO, presenting LVO with subsequent (treated) EVT-induced MeVO. We compared (univariable/multivariable logistic regression) EVT efficacy (eTICI≥2b, 3-month modified Rankin Scale [mRS] 0-2) and safety (EVT-complications [vessel dissection, perforation, persistent-SAH], symptomatic ICH) in all MeVO versus exclusive-LVO, primary MeVO versus exclusive-LVO, EVT-induced secondary MeVO versus exclusive-LVO and EVT-induced secondary MeVO versus primary MeVO.

Results

We included 335 patients: 221 (66.0 %) exclusive-LVO and 114 (34.0 %) MeVO (55 [48.2 %] primary, 59 [51.8 %] secondary). Compared to exclusive-LVO, primary MeVO had higher rates of EVT complications (aOR 3.77 [95%CI 1.58-9.00],p=0.003), lower rates of eTICI≥2b (aOR 0.32 [95%CI 0.12-0.88],p=0.027) and mRS 0-2 (aOR 0.28 [95%CI 0.13-0.63],p=0.002). EVT-induced secondary MeVO had no major differences in efficacy and safety outcomes compared to exclusive-LVO, but a better mRS 0-2 (aOR 8.00 [95%CI 2.12-30.17],p=0.002) compared to primary MeVO.

Conclusions

Primary and EVT-induced secondary MeVO showed different safety/efficacy EVT-related profiles. Dedicated randomized data are needed to identify the best acute reperfusion strategy in the two categories.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鲤鱼寻菡完成签到 ,获得积分10
刚刚
orixero应助Usagi采纳,获得80
3秒前
666完成签到,获得积分10
4秒前
郎吟上邪发布了新的文献求助10
5秒前
5秒前
郎吟上邪完成签到,获得积分10
9秒前
今后应助Falty采纳,获得10
11秒前
NexusExplorer应助Janus采纳,获得10
13秒前
合适的初蓝完成签到 ,获得积分10
13秒前
CipherSage应助纯真路灯采纳,获得10
14秒前
anlikek发布了新的文献求助20
14秒前
huishoushen完成签到 ,获得积分10
16秒前
科研通AI6.2应助w野采纳,获得10
16秒前
16秒前
科研通AI6.2应助包包凌采纳,获得10
16秒前
LENZ完成签到,获得积分10
16秒前
上帝开玩笑完成签到,获得积分10
17秒前
日月不失其体完成签到 ,获得积分10
17秒前
初一完成签到 ,获得积分10
18秒前
追寻博涛完成签到,获得积分10
18秒前
落后乘风完成签到 ,获得积分10
18秒前
19秒前
Lison完成签到,获得积分10
21秒前
zsm668发布了新的文献求助10
22秒前
lee关闭了lee文献求助
23秒前
科目三应助撒野胖嘟嘟采纳,获得10
23秒前
酷波er应助熊如懿小主采纳,获得20
23秒前
24秒前
26秒前
molihuakai应助zzs采纳,获得10
26秒前
郁启蒙完成签到 ,获得积分10
27秒前
ComeOn发布了新的文献求助10
27秒前
沈博哲发布了新的文献求助10
28秒前
29秒前
30秒前
Konstantin关注了科研通微信公众号
30秒前
30秒前
31秒前
遛狗儿发布了新的文献求助10
31秒前
雨中逢花完成签到 ,获得积分10
32秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7738436
求助须知:如何正确求助?哪些是违规求助? 9287523
关于积分的说明 20183708
捐赠科研通 7316346
什么是DOI,文献DOI怎么找? 3305865
关于科研通互助平台的介绍 2458222
邀请新用户注册赠送积分活动 2315758